TAYLOR KRINGS: Open Payments
NPI 1598376279 · MIDLAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,388 in 158 payments from 21 companies in 2025. Trend: 2023 $2,048 · 2024 $2,266 · 2025 $3,388
Food & beverage: $3,256Education: $132
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 23 | $533 |
| Regeneron Healthcare Solutions, Inc. | 20 | $488 |
| GENZYME CORPORATION | 12 | $434 |
| Genentech USA, Inc. | 9 | $248 |
| GlaxoSmithKline, LLC. | 17 | $219 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $197 |
| Amgen Inc. | 11 | $175 |
| Novartis Pharmaceuticals Corporation | 12 | $173 |
| ARS Pharmaceuticals Operations, Inc. | 11 | $163 |
| LEO Pharma Inc. | 6 | $147 |
Products named: DUPIXENT, TEZSPIRE, Xolair, FASENRA, OCTAGAM IMMUNE GLOBULIN (HUMAN), HYQVIA, NEFFY, ADBRY.
Industry payments across TX — which companies pay providers there.
